How the Body Responds to Glucagon in Type 2 Diabetes With Fatty Liver
Tests the body's response to glucagon in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Glucagon Resistance in Patients With MASLD and T2DM
Key facts
- Where
- Aarhus, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 70 years old?
Source: NCT07246421, who can take part
Where in Denmark
- Aarhus University HospitalAarhus, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Aarhus
- Trial code
- NCT07246421
- Record updated
- 4 February 2026
- Original description
The goal of this clinical trial is to investigate the sensitivity to glucagon in patients with type 2 diabetes mellitus (T2DM), with and without metabolic associated fatty liver disease (MASLD).Read full original descriptionShow less
Mechanisms for Glucagon Resistance as Driver of Metabolic Associated Steatotic Liver Disease and Cardiovascular Disease in Humans With Type 2 Diabetes
The goal of this clinical trial is to investigate the sensitivity to glucagon in patients with type 2 diabetes mellitus (T2DM), with and without metabolic associated fatty liver disease (MASLD).
The main questions it aims to answer are:
1. Is the sensitivity to glucagon with respect to hepatic FA oxidation and suppression of VLDL-TG secretion impaired in humans with T2DM and MASLD? 2. Is glucagon resistance and MASLD reflected in an aberrated lipidomic/metabolomic profile in blood and adipose tissue?
Researchers will compare patients with T2DM with and without MASLD to see if the response to basal and high levels of glucagon differs between the groups.
Participants will attend 2 short visits and 1 full-day visit, including:
* Body scan (DXA) to check fat and bone composition * MRI to measure liver fat. * Blood tests. * Ultrasound to check liver stiffness and scarring. * Fat biopsies * 8-hour hormone (including glucagon) and tracer infusion * PET-CT scans
Inclusion: BMI > 26 kg/m²; confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) min. 6 months prior enrollment; steatosis FF% > 5,6% on MR spectroscopy for MAFLD group.
Exclusion: Blood donation within the last 3 months prior to the study day; Previous acute myocardial infarction (AMI); Current or previous malignant disease; Clinical symptoms of heart failure; Current or previous malignant disease; Known ongoing systemic disease, except for dyslipidaemia and hypertension; Severely dysregulated type 2 diabetes mellitus (haemoglobin A1c ≥ 100 mmol/mol); Regular use of medication that may affect lipid and glucose metabolism, including insulin treatment, regular use of over-the-counter medications, and hormonal contraception. Exceptions:; Participants treated with statins may be included following a 2-week washout period prior to the experimental study day; Participants receiving oral glucose-lowering therapy for T2DM and antihypertensive medication may be included provided that medication is withheld on the study day only; Participants receiving weekly injectable glucagon-like peptide-1 receptor agonists (GLP-1 analogues) may be included following a 1-week washout period prior to the study day; Alcohol abuse (>10 units per week for both sexes) or other substance abuse; Smoking; Participation in studies involving radioactive isotopes within the past 3 months; Pregnancy; C-peptide < 200 pmol/L.